PremiumThe FlyRegulus’ farabursen shows efficacy in Phase 1b kidney disease trial Promising Developments and Strategic Positioning Drive Buy Rating for Regulus Therapeutics Regulus Therapeutics Reports Positive Trial Results and Financials PremiumThe FlyRegulus announces clinical and regulatory updates from its ADPKD program Regulus Therapeutics Reports Q3 2024 Financial Results Regulus reports Q3 EPS (21c), consensus (17c) PremiumThe FlyRegulus reports Q2 EPS (17c), consensus (15c) RGLS Upcoming Earnings Report: What to Expect? Regulus initiated with an Outperform at Oppenheimer 
